Diabetes · Question 51 of 60
Mrs R., 56, has severe overweight and coronary heart disease after a heart attack, but no diabetes. Which statement about GLP-1 receptor agonists is correct?
1 answer is correct. Hard Created with AI
Show answer
Answer
- D In a large trial, semaglutide cut major cardiac events by about one fifth
Explanation
In the SELECT trial (NEJM 2023), semaglutide reduced major cardiovascular events by about 20 per cent in people with overweight and cardiovascular disease but without diabetes. Whether such a drug is suitable is decided by the doctor in each individual case.